Age, CD34+ cell dose, conditioning and pre‐transplant cytopenias can help predict transfusion support in lymphoma patients undergoing autologous stem cell transplantation

Abstract

AbstractBackground and ObjectivesAutologous stem cell transplant (ASCT) is a widely used therapy for lymphoma patients and can nowadays be performed on an outpatient basis. This study aimed to describe transfusion support in lymphoma patients undergoing ASCT and identify increased or prolonged transfusion requirement predictors.Materials and MethodsA retrospective study of all consecutive lymphoma patients undergoing ASCT between 2010 and 2020.ResultsOut of 226 patients, 145 (64%) received red blood cell (RBC) transfusions, whereas all 226 (100%) required platelet transfusion (PT). Transfusions between Day +1 and +30 were higher in patients over 60 (2 [1–4] vs. 2 [0–2] RBC; p = 0.001 and 4 [2–8] vs. 3 [2–4] PT; p < 0.001); patients with pre‐transplant anaemia (4 [2.5–6] vs. 2 [0–2] RBC; p < 0.001 and 5 [3–9] vs. 3 [2–4] PT; p = 0.001); pre‐transplant thrombocytopenia (2 [1–4] vs. 2 [0–2] RBC; p < 0.001 and 4 [3–8.5] vs. 2 [1–3] PT; p < 0.001) or CD34+ cell dose <4 × 106/kg (2 [0–4] vs. 2 [0–2] RBC; p = 0.024 and 4 [2–6] vs. 2 [1–3.5] PT; p < 0.001). RBC transfusion independence was reached later in patients receiving carmustine, cytarabine, etoposide and melphalan (BEAM) (hazard ratio [HR] 1.6; confidence interval [CI] 1.1–2.3) and those requiring RBC before infusion and/or with pre‐transplant anaemia (HR 2.2; CI 1.4–3.4). Age above 60 (HR 1.4; CI 1.0–1.9), BEAM conditioning (HR 1.4; CI 1.0–2.0) and pre‐transplant thrombocytopenia and/or requiring PT before infusion (HR 1.8; CI 1.4–2.5) entailed longer time until PT independence.ConclusionThese four factors (age ≥60 years; BEAM conditioning, CD34+ dose <4 × 106/kg and pre‐transplant cytopenia and/or Day −10 to 0 transfusion) allowed dividing patients into three groups with significant differences between them regarding the time until transfusion independence.